Table 7. Summary of demographic characteristics, dose ranges, and duration of studies of Levomilnacipran ER.

ER: Extended release, OLT: Open-label trial, RCT: Randomized controlled trial, RF: Renal functioning

Studies	Design	Groups (n)	Duration (weeks)	Age (years)	Dose range (mg)
Montgomery SA, et al., 2013 [48]	RCT	Levomilnacipran ER=282	10	18-70	75-100
		Placebo=281
Asnis GM, et al., 2013 [47]	RCT	Levomilnacipran ER 40 mg=181	11	18-65	40-120
		Levomilnacipran ER 80 mg=181
		Levomilnacipran ER 120 mg=183
		Placebo=179
Bakish D, et al., 2014 [44]	RCT	Levomilnacipran ER 40 mg=185	10	18-75	40-80
		Levomilnacipran ER 80 mg=187
		Placebo=185
Grommoll CP, et al., 2014 [50]	RCT	Levomilnacipran ER=175	8	18-80	40-120
		Placebo=182
Sambunaris A, et al., 2014 [49]	RCT	Levomilnacipran ER=222	8	18-80	40-120
		Placebo=220
Chen L, et al., 2015 [42]	OLT	32 in four groups based on RF	Single dose	32-76
Chen L, et al., 2015 [46]	OLT	Levomilnacipran ER and Ketoconazole=34	Variable	18-45	40-120
		Levomilnacipran ER and Carbamezapine=34
		Levomilnacipran ER and Alprazolam=30